ONCT - Oncternal Therapeutics Inc Stock Price, Fair Value and News

8.74USD+0.49 (+5.94%)Market Closed

Market Summary

USD8.74+0.49

Market Closed

5.94%

ONCT Alerts

1 major insider buys recently.

ONCT Stock Price

View Fullscreen

ONCT RSI Chart

ONCT Valuation

Market Cap

25.9M

Price/Earnings (Trailing)

-0.66

Price/Sales (Trailing)

32.95

EV/EBITDA

-0.53

Price/Free Cashflow

-0.8

ONCT Price/Sales (Trailing)

ONCT Profitability

EBT Margin

-5020.51%

Return on Equity

-131.37%

Return on Assets

-107.49%

Free Cashflow Yield

-124.34%

ONCT Fundamentals

ONCT Revenue

Revenue (TTM)

785.0K

Rev. Growth (Yr)

73.68%

Rev. Growth (Qtr)

65.92%

ONCT Earnings

Earnings (TTM)

-39.5M

Earnings Growth (Yr)

19.61%

Earnings Growth (Qtr)

7.08%

Breaking Down ONCT Revenue

Last 7 days

5.9%

Last 30 days

-5.7%

Last 90 days

-10.4%

Trailing 12 Months

2566.3%

How does ONCT drawdown profile look like?

ONCT Financial Health

Current Ratio

6.94

ONCT Investor Care

Shares Dilution (1Y)

4.67%

Diluted EPS (TTM)

-13.43

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	947.0K	862.0K	659.0K	785.0K
2022	4.3M	3.6M	1.9M	1.5M
2021	3.5M	3.8M	5.3M	4.3M
2020	2.5M	2.5M	2.5M	3.4M
2019	2.8M	1.9M	2.2M	2.4M
2018	0	5.4M	3.7M	4.2M
2012	5.5M	0	0	0
2011	45.5M	34.3M	23.0M	11.7M
2010	0	28.7M	42.8M	56.8M
2009	0	0	0	14.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Oncternal Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 08, 2024	wills robert james	bought	27,654	8.9613	3,086	-
Mar 28, 2024	wills robert james	bought	58,602	8.4759	6,914	-
Feb 23, 2024	hale david f	bought	6,454	9.04	714	-
Feb 23, 2024	hale david f	bought	2,404	9.04	266	-
Feb 23, 2024	wills robert james	sold	-8,859	9.04	-980	-
Jan 03, 2024	breitmeyer james b	sold (taxes)	-25,278	0.4961	-50,955	chief executive officer
Jan 03, 2024	vincent richard g	sold (taxes)	-4,399	0.4961	-8,868	chief financial officer
Jan 03, 2024	krishnan rajesh	sold (taxes)	-5,872	0.4961	-11,838	chief technical officer
Jan 03, 2024	breitmeyer james b	sold (taxes)	-2,225	0.4961	-4,485	chief executive officer
Jan 03, 2024	yazji salim	sold (taxes)	-9,794	0.4961	-19,742	chief medical officer

Which funds bought or sold ONCT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	new	-	1,638	1,638	-%
May 01, 2024	BNP PARIBAS FINANCIAL MARKETS	sold off	-100	-1,954	-	-%
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 30, 2024	North Star Investment Management Corp.	reduced	-95.00	-431	2,250	-%
Apr 25, 2024	Valeo Financial Advisors, LLC	sold off	-100	-12,620	-	-%
Apr 25, 2024	Lindbrook Capital, LLC	reduced	-95.00	-26.00	135	-%
Apr 16, 2024	Pasadena Private Wealth, LLC	sold off	-100	-268,100	-	-%
Mar 11, 2024	VANGUARD GROUP INC	unchanged	-	675,746	1,534,020	-%
Feb 15, 2024	JANE STREET GROUP, LLC	sold off	-100	-3,086	-	-%

Are Funds Buying or Selling ONCT?

Are funds buying ONCT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ONCT

No. of Funds

ONCT Alerts

1 major insider buys recently.

Unveiling Oncternal Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	4.85%	2,860,906	SC 13G/A
Jul 08, 2022	blackrock inc.	2.0%	1,005,532	SC 13G
Feb 04, 2022	blackrock inc.	6.5%	3,197,538	SC 13G
Feb 16, 2021	armistice capital, llc	3.0%	1,280,930	SC 13G/A
Feb 16, 2021	cvi investments, inc.	-	0	SC 13G/A
Dec 18, 2020	cvi investments, inc.	-	2,500,000	SC 13G
Dec 18, 2020	hyde joseph r iii	2.99%	1,468,142	SC 13D/A
Jul 23, 2020	shanghai pharmaceuticals (hk) investment ltd	7.7%	1,573,975	SC 13D/A
May 29, 2020	armistice capital, llc	9.1%	1,576,471	SC 13G
Feb 14, 2020	perceptive advisors llc	0%	0	SC 13G/A

Recent SEC filings of Oncternal Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 01, 2024	EFFECT	EFFECT
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 10, 2024	4	Insider Trading
Apr 01, 2024	4	Insider Trading
Mar 08, 2024	S-3	S-3
Mar 07, 2024	8-K	Current Report
Mar 07, 2024	10-K	Annual Report
Feb 27, 2024	4	Insider Trading

Peers (Alternatives to Oncternal Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

Oncternal Therapeutics Inc News

Latest updates

Oncternal Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	65.9%	297,000	179,000	106,000	203,000	171,000	382,000	191,000	746,000	556,000	2,128,000	883,000	748,000	1,588,500	585,000	623,000	578,000	736,500	544,000	674,000	470,000	477,000
Operating Expenses	-6.0%	9,933,000	10,569,000	9,651,000	12,346,000	12,086,000	11,707,000	11,986,000	10,658,000	8,636,000	11,765,000	8,573,000	6,707,000	4,449,500	4,980,000	6,158,000	5,329,000	4,917,500	5,493,000	22,294,000	2,828,000	5,586,000
S&GA Expenses	5.5%	3,263,000	3,094,000	3,074,000	3,315,000	3,288,000	3,265,000	3,225,000	3,679,000	2,618,000	2,802,000	3,381,000	2,794,000	1,463,500	1,933,000	2,343,000	2,633,000	2,349,500	2,385,000	1,619,000	932,000	2,346,000
EBITDA Margin	16.1%	-50.15	-59.73	-45.67	-41.57	-26.42	-20.99	-10.87	-9.13	-9.12	-7.36	-10.35	-11.11	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	8,440,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	16.1%	-50.21	-59.80	-45.72	-41.62	-26.45	-21.02	-10.88	-9.14	-9.13	-7.37	-10.36	-11.12	-	-	-	-	-	-	-	-	-
Net Income	7.1%	-9,164,000	-9,862,000	-8,966,000	-11,487,000	-11,400,000	-11,125,000	-11,741,000	-9,904,000	-8,073,000	-9,630,000	-7,682,000	-5,948,000	-2,557,000	-4,395,000	-5,535,000	-4,738,000	-4,156,000	-4,892,000	-22,846,000	-2,294,000	-5,415,000
Net Income Margin	20.6%	-50.29	-63.30	-49.86	-48.31	-29.64	-21.78	-10.87	-8.18	-7.26	-4.83	-5.41	-5.20	-	-	-	-	-	-	-	-	-
Free Cashflow	-16.4%	-6,419,000	-5,513,000	-9,263,000	-10,969,000	-9,002,000	-11,966,000	-7,130,000	-8,606,000	-6,616,000	-6,380,000	-7,608,000	-5,985,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-15.0%	37.00	43.00	51.00	58.00	69.00	76.00	82.00	85.00	94.00	100	108	114	119	24.00	19.00	18.00	22.00	25.00	31.00	23.00	22.00
Current Assets	-15.1%	36.00	42.00	50.00	58.00	67.00	75.00	81.00	85.00	93.00	100	108	113	118	23.00	18.00	17.00	21.00	24.00	30.00	23.00	21.00
Cash Equivalents	-55.1%	7.00	15.00	16.00	11.00	37.00	71.00	79.00	82.00	91.00	97.00	104	111	117	21.00	17.00	16.00	20.00	23.00	29.00	21.00	21.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00
Liabilities	7.7%	7.00	6.00	6.00	-	8.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Current Liabilities	0.9%	5.00	5.00	5.00	5.00	8.00	8.00	8.00	5.00	5.00	6.00	6.00	6.00	6.00	8.00	9.00	7.00	7.00	7.00	8.00	2.00	4.00
Shareholder's Equity	-18.8%	30.00	37.00	45.00	52.00	61.00	69.00	74.00	80.00	88.00	94.00	103	108	113	16.00	10.00	10.00	14.00	18.00	23.00	21.00	26.00
Retained Earnings	-4.9%	-197	-188	-178	-169	-158	-146	-135	-124	-114	-106	-96.43	-88.70	-82.80	-80.20	-75.80	-70.31	-65.57	-61.42	-56.52	-605	-31.38
Additional Paid-In Capital	1.0%	228	226	224	222	219	215	210	204	202	200	199	197	196	96.00	85.00	81.00	80.00	80.00	79.00	627	2.00
Shares Outstanding	-100.0%	-	59.00	59.00	59.00	-	51.00	50.00	49.00	49.00	49.00	49.00	49.00	49.00	-	-	-	-	-	-	-	-
Float	-	-	-	19.00	-	-	-	0.00	-	-	-	212	-	-	-	27.00	-	-	-	62.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-16.4%	-6,419	-5,513	-9,263	-10,969	-9,002	-11,966	-7,130	-8,606	-6,616	-6,380	-7,608	-5,985	-3,911	-5,327	-4,221	-4,036	-3,045	-3,829	-6,239	-3,633	-2,271
Share Based Compensation	29.2%	2,218	1,717	1,680	1,885	1,802	1,974	1,677	1,978	1,713	1,488	1,836	838	407	407	343	399	315	90.00	63.00	39.00	54.00
Cashflow From Investing	-138.8%	-1,808	4,655	13,852	-16,048	-26,498	-	-	-	-	-	-	-	-	-	-	-	-	-1,604	17,820	-79.00	14,784
Cashflow From Financing	98.0%	-1.00	-49.00	-1.00	1,119	2,014	3,694	3,871	-	1.00	97.00	60.00	459	99,389	9,969	4,819	4.00	-	13.00	-	2.00	16,774

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ONCT Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Grant revenue	$ 785,000	$ 1,490,000
Operating expenses:
Research and development	29,753,000	32,980,000
General and administrative	12,746,000	13,457,000
Total operating expenses	42,499,000	46,437,000
Loss from operations	(41,714,000)	(44,947,000)
Interest income	2,235,000	777,000
Net loss	(39,479,000)	(44,170,000)
Comprehensive income
Unrealized gain (loss) on available-for-sale securities, net	(6,000)	9,000
Comprehensive loss	$ (39,485,000)	$ (44,161,000)
Net loss per share, basic	$ (13.43)	$ (16.8)
Net loss per share, diluted	$ (13.43)	$ (16.8)
Weighted-average shares outstanding, basic	2,940	2,630
Weighted-average shares outstanding, diluted	2,940	2,630

ONCT Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 6,697	$ 37,142
Short-term investments	27,558	26,582
Prepaid and other	1,804	3,566
Total current assets	36,059	67,290
Right-of-use asset	258	87
Other assets	412	1,274
Total assets	36,729	68,651
Current liabilities:
Accounts payable	1,148	2,917
Accrued liabilities	3,877	4,678
Lease, current	173	87
Total current liabilities	5,198	7,682
Deferred compensation	1,334	0
Lease, net of current	145	0
Total liabilities	6,677	7,682
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.001 par value, authorized shares 5,000 at December 31, 2023 and 2022; issued and outstanding shares none	0	0
Common stock, $0.001 par value; authorized shares - 120,000 at December 31, 2023 and 60,000 at 2022; issued and outstanding shares - 2,948 and 2,829 at December 31, 2023 and 2022, respectively	3	3
Additional paid-in capital	227,825	219,257
Accumulated other comprehensive income	3	9
Accumulated deficit	(197,779)	(158,300)
Total stockholders’ equity	30,052	60,969
Total liabilities and stockholders’ equity	$ 36,729	$ 68,651

About Oncternal Therapeutics Inc

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.

CEO	Dr. James B. Breitmeyer M.D., Ph.D.
WEBSITE	oncternal.com
INDUSTRY	Biotechnology
EMPLOYEES	30

Oncternal Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Oncternal Therapeutics Inc? What does ONCT stand for in stocks?

ONCT is the stock ticker symbol of Oncternal Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Oncternal Therapeutics Inc (ONCT)?

As of Thu May 02 2024, market cap of Oncternal Therapeutics Inc is 25.87 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ONCT stock?

You can check ONCT's fair value in chart for subscribers.

What is the fair value of ONCT stock?

You can check ONCT's fair value in chart for subscribers. The fair value of Oncternal Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Oncternal Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ONCT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Oncternal Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ONCT is over valued or under valued. Whether Oncternal Therapeutics Inc is cheap or expensive depends on the assumptions which impact Oncternal Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ONCT.

What is Oncternal Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, ONCT's PE ratio (Price to Earnings) is -0.66 and Price to Sales (PS) ratio is 32.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ONCT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Oncternal Therapeutics Inc's stock?

In the past 10 years, Oncternal Therapeutics Inc has provided -0.049 (multiply by 100 for percentage) rate of return.